Sagimet Biosciences Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

SGMT$10.89+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss (unaudited)

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except for share and per share amounts)


· Three Months Ended September 30, · · Nine Months Ended September 30,
· · 2025 · 2024 · 2025 · 2024
Operating expenses:
Research and development	$9,730	12,653	$32,320	$24,228
General and administrative	4,604	4,249	13,804	12,031
Total operating expenses	14,334	16,902	46,124	36,259
Loss from operations	(14,334)	(16,902)	(46,124)	(36,259)
Other income:
Interest income and other, net	1,426	2,283	4,654	6,893
Total other income	1,426	2,283	4,654	6,893
Net loss	$(12,908)	$(14,619)	$(41,470)	$(29,366)

Net loss per share of Series A and Series B common stock outstanding, basic and diluted	$(0.40)	$(0.45)	$(1.28)	$(0.95)
Weighted-average shares of Series A and Series B common stock outstanding, basic and diluted	32,464,893	32,143,336	32,286,188	31,036,271

Net loss	$(12,908)	$(14,619)	$(41,470)	$(29,366)
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities	41	464	(113)	411
Total comprehensive loss	$(12,867)	$(14,155)	$(41,583)	$(28,955)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.